Should surgeons remove the primary tumor in metastatic breast cancer? new study aims to find out.
NCT ID NCT07586319
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether surgically removing the primary breast tumor (along with standard chemotherapy) helps women with oligometastatic breast cancer—cancer that has spread to only a few spots in the body—live longer. About 110 women in Pakistan will either receive surgery plus chemotherapy or chemotherapy alone. Researchers will track survival, cancer progression, and quality of life over time.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- surgery (mastectomy or breast-conserving surgery)
- What this could lead to
- If successful, this could show that surgery on the primary tumor helps women with limited metastatic breast cancer live longer and have a better quality of life.
- What could go wrong
- This is a small, non-randomized study in one country, so results may not apply widely. Previous trials have shown mixed results, and surgery carries standard risks like infection or complications from anesthesia.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 110 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jun 2026
An estimate. Start dates often move.
- Expected to finish
-
Jun 2031
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥18 years * Histologically confirmed breast carcinoma * Oligometastatic disease (≤5 lesions, less than 3 organs) * ECOG performance status 0-2 * Eligible for systemic therapy and surgery * Informed consent obtained Exclusion Criteria: * Unfit for surgery * Prior locoregional surgery on primary tumor * Visceral crisis
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Survival outcomes are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Department of Surgery and Surgical Oncology
Lahore, Punjab Province, 54910, Pakistan
More trials for these conditions
Other studies related to the condition(s) this trial covers.